KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Assets (2016 - 2025)

Historic Assets for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to $82.7 billion.

  • Gsk's Assets rose 971.34% to $82.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $82.7 billion, marking a year-over-year increase of 971.34%. This contributed to the annual value of $76.0 billion for FY2024, which is 356.76% up from last year.
  • Latest data reveals that Gsk reported Assets of $82.7 billion as of Q3 2025, which was up 971.34% from $79.1 billion recorded in Q2 2025.
  • Gsk's 5-year Assets high stood at $112.1 billion for Q2 2022, and its period low was $60.4 billion during Q1 2022.
  • In the last 5 years, Gsk's Assets had a median value of $76.3 billion in 2024 and averaged $83.1 billion.
  • Its Assets has fluctuated over the past 5 years, first plummeted by 4388.74% in 2022, then surged by 1789.42% in 2023.
  • Gsk's Assets (Quarter) stood at $106.6 billion in 2021, then tumbled by 33.84% to $70.5 billion in 2022, then increased by 3.81% to $73.2 billion in 2023, then rose by 4.21% to $76.3 billion in 2024, then increased by 8.42% to $82.7 billion in 2025.
  • Its Assets was $82.7 billion in Q3 2025, compared to $79.1 billion in Q2 2025 and $76.5 billion in Q1 2025.